Home | Welcome to Contract Pharma   
Last Updated Sunday, May 26 2013
Print RSS Feed

Breaking News

Related Searches: Industry News •
Wyeth Licenses Crucell Technology

July 30, 2007
Crucell N.V. has entered into a co-exclusive PER.C6 and Advac technology license agreement with Wyeth. Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on product sa…  Read More »
Merck & Co., Inc.

July 27, 2007
Kenneth C. Frazier, Merck's executive vice president and general counsel, has been named executive vice president and president, global human health, Merck & Co. Mr. Frazier will oversee more than 30,000 employees and have responsibility fo…  Read More »
Financial Report: Amgen

July 27, 2007
Amgen 2Q Revenues: $3.7 billion (+3%) 2Q Earnings: $1 billion (earnings were $14 million in 2Q2006) YTD Revenues: $7.4 billion (+9%) YTD Earnings: $2.1 billion (+110%) Comments: Worldwide sales of Aranesp were down 10% to $949 mi…  Read More »
Ricerca

July 27, 2007
Mark T. Crane has been appointed vice president, business development and marketing, Ricerca Biosciences, LLC. Mr. Crane joins the company from Bridge Pharmaceutical, Inc. (formerly Gene Logic) and has held similar positions at Quest Pharmaceutical…  Read More »
AstraZeneca To Cut Workforce By 10%

July 26, 2007
AstraZeneca plans to expand its restructuring program and will eliminate 10% of its 2006 workforce, or approximately 7,600 jobs, as part of an effort to reduce costs and save $900 million by 2010. According to chief executive officer, David Brennan,…  Read More »
Financial Report: BMS

July 26, 2007
Bristol-Myers Squibb  2Q Revenues: $4.9 billion (+1%) 2Q Earnings: $706 million (+6%) YTD Revenues: $9.4 billion (-1%) YTD Earnings: $1.4 billion (flat) Comments: Worldwide pharmaceutical sales were flat at $3.9 billion. U.S.…  Read More »
Thermo Fisher to Acquire Qualigens Fine Chemicals

July 26, 2007
Thermo Fisher Scientific, Inc. has entered into an agreement to acquire Qualigens Fine Chemicals, a division of GlaxoSmithKline Pharmaceuticals (GSK India) based in Mumbai. Qualigens is a chemical manufacturer and supplier serving a variety of indust…  Read More »
Merck To Acquire NovaCardia

July 25, 2007
Merck will acquire NovaCardia, Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular diseases, for $350 million. NovaCardia's lead product candidate KW-3902, an adenosine A1 receptor antagonist, is currently in Phase…  Read More »
Wyeth's Pristiq in Limbo for Menopause/Depression

July 25, 2007
Wyeth received an approvable letter from the FDA for Pristiq, a serotonin-norepinephrine reuptake inhibitor (SNRI), currently under review for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. However, th…  Read More »
Galapagos Earns Novartis Milestone

July 25, 2007
Galapagos achieved the second milestone under the antibody collaboration with Novartis for bone-related diseases, triggering a payment of $1 million to Galapagos. Galapagos will pay $750,000 of this amount to ProStrakan as part of their December 2006…  Read More »
Lilly 2Q

July 24, 2007
Eli Lilly & Co. 2Q Revenues: $4.6 billion (+14%) 2Q Earnings: $664 million (-19%) YTD Revenues: $8.9 billion (+13%) YTD Earnings: $1.2 billion (-29%) Comments: Net income was impaired by the purchases of Hypnion and Ivy Animal Heal…  Read More »
MPI Research Expands Tox Offerings

July 24, 2007
MPI Research recently added new toxicology capacity as part of an expansion project. Completed July 20th, the 79,000-sq.-ft. expansion includes the addition of 84 animal rooms, new surgical suites and accommodations for specialized infusion work.…  Read More »
Biogen Idec 2Q

July 24, 2007
Biogen Idec 2Q Revenues: $773 million (+17%) 2Q Earnings: $186 million (net loss of $171 million in 2Q2006) YTD Revenues: $1.5 billion (+17%) YTD Earnings: $318 million (net loss of $48 million in 2Q2006) Comments: Avonex sales rose 8%…  Read More »
Xceleron Adds to U.S. Footprint

July 23, 2007
Xceleron, a provider of analytical strategies for drug development, will expand its U.S. business by signing of a lease on a facility in Germantown, MD. The facility, opening in November 2007, will house a new accelerator mass spectrometer (AMS) and…  Read More »
Schering-Plough 2Q

July 23, 2007
Schering-Plough 2Q Revenues: $3.2 billion (+13%) 2Q Earnings: $539 million (+108%) YTD Revenues: $6.2 billion (+15%) YTD Earnings: $1.1 billion (+75%) Comments: SP's Remicade sales were up 28% to $394 million. Nasonex sales grew 22% t…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: